Related Experiment Video
Updated: May 6, 2026

SILAC Based Proteomic Characterization of Exosomes from HIV-1 Infected Cells
Published on: March 3, 2017
A study to investigate HLA-G targeted exosome (SOB100) in healthy subjects
Kai-Jie Yang1, Ni-Yen Yu1, Ronald Goldwater2
1Department of Research & Clinical Development, Shine-On Biomedical, Taichung City, Taiwan.
Abstract:
To investigate the safety profile and tolerability of SOB100, a targeted exosome drug delivery platform derived from HEK293T cells engineered with an anti-Human Leukocyte Antigen G(HLA-G) nanobody. An open-label, dose-escalation Phase I with a total of fifteen subjects will be enrolled in five cohorts, three subjects in each cohort, comprising one single-ascending dose (SAD) cohort or multiple-ascending dose (MAD) cohorts (low, medium, and high dose levels). This will be the first in-human study to evaluate the safety and tolerability of HLA-G targeted exosome (SOB100) in healthy volunteers.Trial registration number: NCT07219940 (ClinicalTrials.gov).
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Bioavailability Study Design: Healthy Subjects Versus Patients

